The New England journal of medicine
-
Editorial Comment
Been there, not done that--melanoma in the age of molecular therapy.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. ⋯ Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
-
Editorial Comment
Fluid resuscitation in acute illness--time to reappraise the basics.